Clinical Trial: Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498517) titled 'Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT' on March 23.

Brief Summary: This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition...